U.S.-Based Diagnostic Reagent Manufacturing & Component Sourcing

The contract requires the domestic formulation, blending, and manufacturing of in vitro diagnostic reagents with a strict requirement that at least 55 percent of all component costs must be sourced from U.S.-based suppliers. The work must be performed entirely within the United States and aligns with NAICS code 325412, which categorizes it under medical and diagnostic laboratory manufacturing. This is a subcontract opportunity issued by the Department of Veterans Affairs through the 262-NETWORK Contract Office 22, with responses due by May 20, 2026, at 2:00 PM Eastern Time. The solicitation emphasizes U.S. supply chain integrity, targeting entities capable of full-scale production while maintaining compliance with domestic sourcing thresholds. No set-aside designation has been specified, and while no point of contact or detailed performance location is provided, all activities must take place domestically to meet the contractual obligations.